A September 23 Federal Register notice names nineteen jurisdictions whose specialty medicines qualify for a zero rate under the Section 232 pharmaceutical tariff. Canada is not among them. The adjustment takes effect on September 29, leaving Canadian life sciences exporters at the 100 percent baseline while the European Union, Japan, the United Kingdom and sixteen others go to zero.
OTTAWA, September 25, 2026
The United States Department of Commerce published guidance on September 23 setting out how it will administer zero rate treatment for specialty pharmaceutical products under the Section 232 pharmaceutical tariff, and the list of jurisdictions that qualify automatically does not include Canada.
The notice, titled “Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020,” takes effect at 12:01 a.m. Eastern time on September 29, with an earlier effective date of July 31, 2026 for companies named in Annex III of the underlying proclamation.
For Canadian life sciences exporters, the practical result is a competitive gap measured in percentage points of landed cost. A cell therapy product shipped to an American hospital from Dublin, Basel, Tokyo or Seoul can enter at zero. The same class of product shipped from Toronto, Montreal or Mississauga faces the 100 percent ad valorem baseline unless the exporting company successfully petitions Commerce for a product specific finding of urgent American health need.
The United States imported approximately $3.76 billion in pharmaceutical products from Canada in 2025. Not all of that falls within the specialty categories the new guidance covers, but the categories are commercially significant and heavily weighted toward exactly the high value, low volume products where Canadian firms have built export positions.
What the notice does
Proclamation 11020, issued on April 2, 2026, imposed tariffs on pharmaceutical imports under Section 232 of the Trade Expansion Act of 1962, on national security grounds. The baseline rate is 100 percent ad valorem. Implementation for patented pharmaceuticals began on July 31, 2026, when United States Customs and Border Protection issued its first entry guidance.
The September 23 notice creates the mechanism for reducing that rate to zero for a defined set of specialty products. Eligibility runs through one of two doors.
The first door is jurisdictional. Products originating in jurisdictions that have concluded trade and security framework agreements with the United States receive the zero rate automatically for covered categories. Nineteen jurisdictions qualify: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam.
The second door is product and company specific. A firm whose product does not originate in an eligible jurisdiction may petition for zero rate treatment on the basis that the product meets an urgent American health need. These determinations are made individually and are described in the notice as fact specific and company specific.
The covered categories are narrower than the pharmaceutical tariff as a whole but include several of the most commercially important segments in modern medicine. They are: drugs for which all approved indications carry orphan designation; nuclear medicines, meaning radioactive drugs and biologics; plasma derived therapies; fertility drugs; cell therapy products; gene therapy products; antibody drug conjugates; medical countermeasures for chemical, biological, radiological and nuclear threats; and animal health products.
The tariff classification architecture is extensive. Annex I of the proclamation lists more than two hundred pharmaceutical specific Harmonized Tariff Schedule codes, ranging from 2918.99.3000 through 3006.93.8000. The September 23 notice also creates a new heading, 9903.04.70, for products imported solely for use in clinical trials, research and development, or other non commercial applications.
The technical corrections
Alongside the zero rate mechanism, the notice makes five corrections to Annex I and one to Annex IV that materially change scope for some importers.
The definition of generic pharmaceutical articles is clarified to include unpatented animal health products. The new clinical trial and research heading, 9903.04.70, is established. The definitions distinguishing finished pharmaceuticals from pharmaceutical ingredients are refined. And five Harmonized Tariff Schedule codes are removed from Annex IV where they overlapped with Annex I: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00 and 3004.49.00.
That last item is not housekeeping. Where a code sat in two annexes with different treatment, importers have been making classification judgments in conditions of genuine ambiguity since July. The removal resolves the overlap prospectively, and importers who have filed entries on those five codes since July 31 should be reviewing whether the treatment they applied matches the treatment the corrected annexes now specify.
The clinical trial heading is equally consequential for Canadian firms, many of which ship investigational material to American trial sites. Material moving for clinical, research and development or other non commercial purposes now has a dedicated classification rather than being forced into commercial headings that carry the full duty. For a Canadian biotechnology company running a multi site American trial, that is the difference between a manageable logistics cost and a programme threatening one.
How the petition route works
For Canadian exporters, the urgent health need petition is the only available path to the zero rate, and the notice sets out what a submission must contain.
Petitions go to Commerce electronically at pharma232@bis.doc.gov. Each submission must identify the organisation and an authorised representative with contact details; the Harmonized Tariff Schedule classification, with ten digit classification preferred; the product name, brand name, investigational new drug number and active ingredients; the product category claimed under the covered list; the country of origin and the country of export; the importer of record, including its importer of record number; the manufacturer’s name and address; and a detailed rationale explaining the urgent health need.
The rationale is where these submissions will be won or lost. The notice states that it should address the type of disease the product treats and an assessment of alternative therapies or the lack of alternative therapies for that disease, the number of American patients who use the product, and whether the product is available in other jurisdictions.
That last element deserves attention from Canadian applicants, because it cuts both ways. A product available from an eligible jurisdiction is a product for which the United States has a zero rate alternative source, which weakens the urgency argument. A product available only from Canada is a stronger case on urgency but a narrower commercial base from which to fund the petition process.
Commerce consults the Office of the United States Trade Representative and the Secretary of Health and Human Services before deciding. Applicants receive written notification. Customs and Border Protection then administers the adjusted rate at the point of entry summary filing.
Submissions are accepted on an ongoing basis, with no stated deadline beyond the September 29 implementation date. Confidential business information is protected under the Trade Secrets Act and under exemptions 3 and 4 of the Freedom of Information Act, with dissemination limited to personnel with a legitimate need to know within Commerce, USTR and other executive branch agencies.
There is no published processing time. For a Canadian company with product moving weekly, the absence of a service standard is itself a planning problem, because the tariff applies at entry regardless of whether a petition is pending.
Why Canada is not on the list
The nineteen jurisdiction list is defined by the existence of a trade and security framework agreement with the United States. Canada does not have one.
That is the direct answer, and it reflects the state of the bilateral relationship rather than any assessment of Canadian pharmaceutical manufacturing. Canada United States trade negotiations collapsed in August 2026. Since then the two countries have exchanged tariff measures: American action under Section 338 of the Tariff Act of 1930 against Canadian dairy, alcoholic beverages and motor vehicle goods, escalating to an import prohibition scheduled for September 29; and Canadian counter tariffs on roughly $20 billion of American exports, effective September 8.
The pharmaceutical zero rate list is therefore best understood as one of the places where the absence of a framework agreement shows up as a concrete commercial cost. It is not a retaliation measure aimed at Canada. It is a benefit extended to countries that concluded agreements, from which Canada is excluded by virtue of not having concluded one.
The composition of the list underlines the point. It includes the European Union, Japan, the United Kingdom, Korea, Switzerland and Taiwan, which together account for most of the advanced biologics manufacturing capacity outside North America. It also includes India, Indonesia, Malaysia, Thailand, Vietnam, Bangladesh and Cambodia, along with Argentina, Ecuador, El Salvador, Guatemala, Jordan and North Macedonia. The breadth suggests that framework agreements have been concluded at pace across a wide range of trading partners, which makes Canada’s absence more conspicuous rather than less.
The competitive arithmetic
The commercial effect is easiest to see in the categories where products are effectively fungible from the buyer’s perspective.
Plasma derived therapies are a clear example. American hospital systems and specialty distributors purchasing immunoglobulin or albumin have multiple qualified international sources. A 100 percent duty differential against Canadian product does not require a purchasing manager to prefer European supply. It requires only that they follow ordinary cost discipline.
Nuclear medicines present a more complicated picture, and one where Canada has historically held a strong position. Radioisotope products have short half lives and supply chains built around proximity and reliability rather than price alone. A duty differential is a serious problem, but it does not eliminate the logistical advantage of a Canadian source serving American hospitals. It does, however, invite qualification of alternative suppliers, and once a hospital system has qualified a second source, the switching cost that protects the incumbent is gone permanently.
Cell and gene therapy products sit somewhere between. These are high value, often patient specific, and frequently manufactured under arrangements where the treatment site and the manufacturing site are linked by protocol. Substitution is harder. But new programme placement decisions, meaning where a company chooses to build its next manufacturing capacity, are made on a ten year horizon, and a 100 percent tariff differential against Canadian sites is a powerful input into that decision.
Animal health products, newly clarified to include unpatented articles within the generic definition, are the most price sensitive category on the list and therefore the most immediately exposed.
Orphan drugs are the category where the urgent health need petition is most likely to succeed, because the definitional overlap is substantial. A drug whose approved indications are all orphan designated is by construction a drug treating a rare disease with limited alternatives, which is close to the rationale the notice asks applicants to establish.
How this compares with steel and aluminium
Canadian exporters have been through a Section 232 process before, and the differences between the metals precedent and the pharmaceutical one are instructive.
When Section 232 duties were applied to steel and aluminium, Canada eventually secured relief through a negotiated arrangement, and in the interim the exclusion process operated at the product level through a public docket where domestic producers could object. That structure was slow and heavily criticised, but it was transparent. Applicants could see competing submissions and could anticipate objections.
The pharmaceutical mechanism is different in three ways that matter for planning.
First, it is not adversarial in the same sense. There is no published objection process in which an American manufacturer formally contests a Canadian applicant’s submission. Commerce consults USTR and the Department of Health and Human Services, and the determination is described as fact specific and company specific. That removes a source of delay but also removes visibility. An applicant cannot see what arguments are being made on the other side, because they are being made inside government rather than on a docket.
Second, the criterion is public health rather than domestic capacity. In the metals context, the question was broadly whether an American producer could supply the article. Here the question is whether American patients have an urgent need, assessed against alternative therapies, patient numbers and availability elsewhere. That is a clinical and epidemiological argument rather than an industrial one, and it calls for different evidence: prescribing data, treatment guidelines, formulary listings and clinical literature rather than mill capacity and lead times.
Third, and most consequentially, there is a jurisdictional shortcut in the pharmaceutical mechanism that had no real equivalent in metals. Nineteen jurisdictions receive the zero rate automatically because their governments concluded framework agreements. That converts what would otherwise be a company by company administrative burden into a diplomatic outcome, and it means that a Canadian firm’s competitive position in the American market now depends on a negotiation it cannot participate in.
For Canadian life sciences companies, the strategic conclusion follows from that third point. Petition work is necessary and should proceed, product by product, on the strongest cases first. But petitions are mitigation. The resolution is jurisdictional, and it arrives, if it arrives, through a bilateral framework agreement rather than through an inbox at the Bureau of Industry and Security.
Timing and the practical horizon
The notice sets no deadline for urgent health need submissions and publishes no processing standard. Commerce accepts them on an ongoing basis. Customs and Border Protection applies whatever rate is in effect at the time of entry summary filing, which means a pending petition confers no interim relief.
That combination creates a cash flow problem distinct from the tariff itself. A Canadian exporter shipping weekly into the United States will pay the 100 percent rate on every entry while its petition sits under review, and there is no published mechanism for retroactive refund of duties paid before an approval. Firms should therefore model the tariff as a real and continuing cost for the full period of review, not as a temporary imposition that a successful petition will unwind.
For products with thin margins, that arithmetic may argue for pausing American shipments rather than shipping at a loss while awaiting a decision. For products where continuity of supply to patients is clinically important, pausing is not an option, and the duty becomes a cost of maintaining the relationship. The distinction between those two cases is the most important commercial judgment Canadian exporters in the covered categories will make this quarter, and it should be made deliberately rather than by default.
What Canadian exporters should do now
The first step is a classification audit against the corrected annexes rather than the April versions. Five codes moved out of Annex IV, a new heading was created for clinical and research material, and the finished product versus ingredient definitions were refined. Any Canadian exporter operating on a classification opinion written before September 23 is operating on an outdated document.
The second step is to determine, product by product, whether the goods fall within one of the nine covered specialty categories. Products outside those categories are not eligible for the zero rate through either door, and for those lines the question is not petition strategy but pricing, contract allocation of duty and, in some cases, market participation.
The third step, for products inside the categories, is to assess the urgent health need case honestly before investing in a petition. The strongest candidates are products with no or few therapeutic alternatives, a meaningful American patient population, and limited availability from the nineteen eligible jurisdictions. The weakest are products readily supplied from the European Union or Japan. A firm with several products should sequence its petitions, leading with the strongest case, since a first approval establishes a working relationship with the reviewing officials that later submissions can build on.
The fourth step concerns clinical and research material specifically. Canadian firms shipping investigational product to American trial sites should confirm that their brokers are using heading 9903.04.70 where the material qualifies. This is the single highest value classification change in the notice for the Canadian biotechnology sector, and it will be missed by any broker still working from July guidance.
The fifth step is contractual. Supply agreements with American customers that allocate duty to the seller, or that were silent because no duty was contemplated when they were signed, now carry exposure at 100 percent of product value. Those agreements need review, and renewal negotiations should address the tariff explicitly rather than leaving it to a general change in law clause.
Finally, Canadian firms should track the framework agreement question at the government relations level. The nineteen jurisdiction list is not static. If Canada and the United States conclude a trade and security framework agreement, the jurisdictional door opens and the petition route becomes unnecessary. That is a policy outcome no individual company can deliver, but it is the outcome that would resolve the problem comprehensively rather than product by product, and industry associations including those representing Canadian biopharmaceutical manufacturers have an obvious interest in making the case for it.
The stakes
Canada’s pharmaceutical and life sciences sector has been one of the more durable parts of the export base through two years of trade disruption, insulated in part because pharmaceutical products sat outside the earlier rounds of tariff action. Proclamation 11020 ended that insulation in April. The September 23 notice has now established which countries get relief from it, and Canada is outside that circle.
Four days remain before the adjustment takes effect. For most Canadian exporters in the covered categories, there is no realistic prospect of a completed petition in that window. The work available in the next four days is classification accuracy, contract review and petition preparation. The work available after that is making the case, product by product, that American patients need what Canadian manufacturers make.